A phase I open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, immunogenicity and clinical activity of the antibody drug conjugate GSK2857916 in subjects with relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA
Phase of Trial: Phase I
Latest Information Update: 18 Aug 2017
At a glance
- Drugs GSK 2857916 (Primary)
- Indications Haematological malignancies; Multiple myeloma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 10 Aug 2017 Planned End Date changed from 1 Jul 2018 to 12 Nov 2018.
- 10 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 12 Nov 2017.
- 30 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History